-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD – -First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center– DURHAM, N.C. --(BUSINESS WIRE)--Aug. 24, 2026-- Precision BioSciences, Inc.
- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 31, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial
– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy – DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 10, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000